|
1
|
Wolfgang CL, Herman JM, Laheru DA, et al:
Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paulson AS, Tran Cao HS, Tempero MA and
Lowy AM: Therapeutic advances in pancreatic cancer.
Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peng F, Wei YQ, Tian L, et al: Induction
of apoptosis by norcantharidin in human colorectal carcinoma cell
lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin
Oncol. 128:223–230. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen YN, Chen JC, Yin SC, et al: Effector
mechanisms of norcantharidin-induced mitotic arrest and apoptosis
in human hepatoma cells. Int J Cancer. 100:158–165. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huan SK, Lee HH, Liu DZ, Wu CC and Wang
CC: Cantharidin-induced cytotoxicity and cyclooxygenase 2
expression in human bladder carcinoma cell line. Toxicology.
223:136–143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li W, Xie L, Chen Z, et al: Cantharidin, a
potent and selective PP2A inhibitor, induces an oxidative
stress-independent growth inhibition of pancreatic cancer cells
through G2/M cell-cycle arrest and apoptosis. Cancer Sci.
101:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li W, Chen Z, Zong Y, et al: PP2A
inhibitors induce apoptosis in pancreatic cancer cell line PANC-1
through persistent phosphorylation of IKKalpha and sustained
activation of the NF-kappaB pathway. Cancer Lett. 304:117–127.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li W, Chen Z, Gong FR, et al: Growth of
the pancreatic cancer cell line PANC-1 is inhibited by protein
phosphatase 2A inhibitors through overactivation of the c-Jun
N-terminal kinase pathway. Eur J Cancer. 47:2654–2664. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li W, Li DM, Chen K, et al: Development of
a gene therapy strategy to target hepatocellular carcinoma based
inhibition of protein phosphatase 2A using the alpha-fetoprotein
promoter enhancer and pgk promoter: an in vitro and in vivo study.
BMC Cancer. 12:5472012. View Article : Google Scholar
|
|
10
|
Millward TA, Zolnierowicz S and Hemmings
BA: Regulation of protein kinase cascades by protein phosphatase
2A. Trends Biochem Sci. 24:186–191. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janssens V, Goris J and Van Hoof C: PP2A:
the expected tumor suppressor. Curr Opin Genet Dev. 15:34–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen YJ, Kuo CD, Tsai YM, et al:
Norcantharidin induces anoikis through Jun-N-terminal kinase
activation in CT26 colorectal cancer cells. Anticancer Drugs.
19:55–64. 2008. View Article : Google Scholar
|
|
13
|
Schweyer S, Bachem A, Bremmer F, et al:
Expression and function of protein phosphatase PP2A in malignant
testicular germ cell tumours. J Pathol. 213:72–81. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tanaka T, Masuda H, Naito M and Tamai H:
Pretreatment with 5-fluorouracil enhances cytotoxicity and
retention of DNA-bound platinum in a cisplatin resistant human
ovarian cancer cell line. Anticancer Res. 21:2463–2469.
2001.PubMed/NCBI
|
|
15
|
McClay EF, McClay MT, Monroe L, Jones JA
and Winski PJ: A phase II study of high dose tamoxifen and weekly
cisplatin in patients with metastatic melanoma. Melanoma Res.
11:309–313. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sudo K, Monsma FJ Jr and Katzenellenbogen
BS: Antiestrogen-binding sites distinct from the estrogen receptor:
subecellular localization, ligand specificity, and distribution in
tissues of the rat. Endocrinology. 112:425–434. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lam HY: Tamoxifen is a calmodulin
antagonist in the activation of cAMP phosphodiesterase. Biochem
Biophys Res Commun. 118:27–32. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O’Brian CA, Liskamp RM, Solomon DH and
Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer
Res. 45:2462–2465. 1985.PubMed/NCBI
|
|
19
|
Su HD, Mazzei GJ, Vogler WR and Kuo JF:
Effect of tamoxifen, a nonsteroidal antiestrogen, on
phospholipid/calcium-dependent protein kinase and phosphorylation
of its endogenous substrate proteins from the rat brain and ovary.
Biochem Pharmacol. 34:3649–3653. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carmichael J, DeGraff WG, Gazdar AF, Minna
JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: assessment of chemosensitivity testing. Cancer
Res. 47:936–942. 1987.PubMed/NCBI
|
|
21
|
Mandlekar S and Kong AN: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Andrén-Sandberg A, Hoem D and Bäckman PL:
Other risk factors for pancreatic cancer: hormonal aspects. Ann
Oncol. 10(Suppl 4): 131–135. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jordan VC and Morrow M: Tamoxifen,
raloxifene, and the prevention of breast cancer. Endocr Rev.
20:253–278. 1999.PubMed/NCBI
|
|
24
|
Tomao S, Romiti A, Massidda B, et al: A
phase II study of gemcitabine and tamoxifen in advanced pancreatic
cancer. Anticancer Res. 22:2361–2364. 2002.PubMed/NCBI
|
|
25
|
Eckel F, Lersch C, Lippl F, Assmann G and
Schulte-Frohlinde E: Phase II trial of cyclophosphamide,
leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in
pancreatic cancer. J Exp Clin Cancer Res. 19:295–300. 2000.
|
|
26
|
Efferth T, Fu YJ, Zu YG, et al: Molecular
target-guided tumor therapy with natural products derived from
traditional Chinese medicine. Curr Med Chem. 14:2024–2032. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chan E, Tan M, Xin J, Sudarsanam S and
Johnson DE: Interactions between traditional Chinese medicines and
Western therapeutics. Curr Opin Drug Discov Devel. 13:50–65.
2010.PubMed/NCBI
|
|
28
|
Jiang JC: English translation of terms of
prescription-monarch, minister, assistant and guide. Zhongguo Zhong
Xi Yi Jie He Za Zhi. 30:11052010.(In Chinese).
|
|
29
|
Wang L, Zhou GB, Liu P, et al: Dissection
of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis
as an effective treatment for promyelocytic leukemia. Proc Natl
Acad Sci USA. 105:4826–4831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Edmond KM, Kortsalioudaki C, Scott S, et
al: Group B streptococcal disease in infants aged younger than 3
months: systematic review and meta-analysis. Lancet. 379:547–556.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu JJ, Ai CZ, Liu Y, et al: Interactions
between phytochemicals from traditional Chinese medicines and human
cytochrome P450 enzymes. Curr Drug Metab. 13:599–614. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tseng YP, Wu YC, Leu YL, Yeh SF and Chou
CK: Scutellariae radix suppresses hepatitis B virus production in
human hepatoma cells. Front Biosci (Elite Ed). 2:1538–1547. 2010.
View Article : Google Scholar
|
|
33
|
Li HB, Ge YK, Zhang L and Zheng XX:
Astragaloside IV improved barrier dysfunction induced by acute high
glucose in human umbilical vein endothelial cells. Life Sci.
79:1186–1193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lan TH, Xu ZW, Wang Z, et al: Ginsenoside
Rb1 prevents homocysteine-induced endothelial dysfunction via
PI3K/Akt activation and PKC inhibition. Biochem Pharmacol.
82:148–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zong Y, Ai QL, Zhong LM, et al:
Ginsenoside Rg1 attenuates lipopolysaccharide-induced inflammatory
responses via the phospholipase C-gamma1 signaling pathway in
murine BV-2 microglial cells. Curr Med Chem. 19:770–779. 2012.
View Article : Google Scholar
|
|
36
|
He CL, Yi PF, Fan QJ, et al: Xiang-Qi-Tang
and its active components exhibit anti-inflammatory and
anticoagulant properties by inhibiting MAPK and NF-kappaB signaling
pathways in LPS-treated rat cardiac microvascular endothelial
cells. Immunopharmacol Immunotoxicol. 35:215–224. 2013. View Article : Google Scholar
|
